Centauri Therapeutics is an immunotherapy company, with a unique and proprietary platform technology applicable across a wide range of therapeutic indications. The Company’s initial focus is on infectious diseases, driven by an urgent unmet need for anti-infectives to treat the most vulnerable and at-risk patients. Centauri also has strong initial proof-of-concept data in oncology. Centauri’s Alphamer platform has a unique mechanism of action, utilising an antibody recruiting molecule to harness the body’s natural immune response, and redirect antibodies to target diseases.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?